The 2017 European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myelogenous leukemia (AML) in adults includes updates based on several recent advances in AML, most notably advances in knowledge of the genomic landscape of the disease.
The recommendations include the development of assays for genetic testing and detecting minimal residual disease (MRD), as well as updates on novel anti-leukemic agents. The guidelines parallel the current update to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia.
The recommendations include a revision of the genetic categorization to favorable, intermediate and adverse for risk stratification, a proposal for a response category based on MRD status, as well as criteria for progressive disease. The report includes guidelines for:
- Molecular landscape of AML
- Diagnostic procedures
- Prognostic factors
- Response criteria and outcome measures
- MDS-AML overlap/secondary AML
- Current AML therapy
- Relapsed disease and primary refractory disease
- Therapy-related AML
- Clinical trials
- Novel therapies
- Management of special situations
- Supportive care